Skip to main content
Premium Trial:

Request an Annual Quote

Armonica Technologies Wins $349K SBIR Grant From NHGRI

NEW YORK – Armonica Technologies, a University of New Mexico spinout commercializing a nanopore DNA sequencing method, said on Monday it has received a two-year Small Business Innovation Research Phase I grant from the National Human Genome Research Institute.

Armonica will receive $349,200 in fiscal year 2021. The Albuquerque, New Mexico-based company is partnering with UNM researcher and Cofounder Jeremy Edwards as part of the award.

Using nanochannels that help capture optical spectra of DNA molecules based on the principle of Raman scattering, Armonica's technology can generate long reads of single molecules, including direct readout of epigenetic modifications. 

"Armonica continues to make significant improvements to the performance of our groundbreaking technology, and we are honored that the NIH has awarded us this grant in support of our product development goals," CEO Victor Esch said in a statement.

The grant adds to $1.5 million in seed funding from New Mexico's Catalyst Fund.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.